Suzanne M Scheaffer
Overview
Explore the profile of Suzanne M Scheaffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malladi S, Jaiswal D, Ying B, Alsoussi W, Darling T, Dadonaite B, et al.
bioRxiv
. 2024 Dec;
PMID: 39713327
SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. It remains unclear how the continuous evolution of the virus impacts the breadth of the...
2.
Case J, Sanapala S, Dillen C, Rhodes V, Zmasek C, Chicz T, et al.
Cell Host Microbe
. 2024 Nov;
32(12):2131-2147.e8.
PMID: 39561781
The continued emergence of SARS-CoV-2 variants and the threat of future Sarbecovirus zoonoses have spurred the design of vaccines that can induce broad immunity against multiple coronaviruses. Here, we use...
3.
Dmytrenko O, Das S, Kovacs A, Cicka M, Liu M, Scheaffer S, et al.
J Virol
. 2024 Aug;
98(9):e0117924.
PMID: 39207134
Cardiovascular manifestations of coronavirus disease 2019 (COVID-19) include myocardial injury, heart failure, and myocarditis and are associated with long-term disability and mortality. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA...
4.
Ying B, Liang C, Desai P, Scheaffer S, Elbashir S, Edwards D, et al.
J Virol
. 2024 Aug;
98(9):e0057424.
PMID: 39194250
Boosting with mRNA vaccines encoding variant-matched spike proteins has been implemented to mitigate their reduced efficacy against emerging SARS-CoV-2 variants. Nonetheless, in humans, it remains unclear whether boosting in the...
5.
Liang C, Raju S, Liu Z, Li Y, Arunkumar G, Case J, et al.
Nature
. 2024 May;
630(8018):950-960.
PMID: 38749479
Immune imprinting is a phenomenon in which prior antigenic experiences influence responses to subsequent infection or vaccination. The effects of immune imprinting on serum antibody responses after boosting with variant-matched...
6.
Desautels T, Arrildt K, Zemla A, Lau E, Zhu F, Ricci D, et al.
Nature
. 2024 May;
629(8013):878-885.
PMID: 38720086
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs and revealed how quickly viral escape can curtail effective options. When the SARS-CoV-2 Omicron variant emerged in...
7.
Bricker T, Joshi A, Soudani N, Scheaffer S, Patel N, Guebre-Xabier M, et al.
J Virol
. 2024 Feb;
98(3):e0120623.
PMID: 38305154
Importance: As SARS-CoV-2 continues to evolve, there may be a need to update the vaccines to match the newly emerging variants. Here, we compared the protective efficacy of the updated...
8.
Zimmerman O, Doss A, Ying B, Liang C, Mackin S, Davis-Adams H, et al.
JCI Insight
. 2024 Jan;
9(3).
PMID: 38175703
Immunoglobulin (IG) replacement products are used routinely in patients with immune deficiency and other immune dysregulation disorders who have poor responses to vaccination and require passive immunity conferred by commercial...
9.
Stewart-Jones G, Elbashir S, Wu K, Lee D, Renzi I, Ying B, et al.
Sci Transl Med
. 2023 Sep;
15(713):eadf4100.
PMID: 37703353
With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed and evaluated domain-based mRNA vaccines...
10.
Case J, Scheaffer S, Darling T, Bricker T, Adams L, Harastani H, et al.
J Virol
. 2023 Sep;
97(9):e0062823.
PMID: 37676002
The continued evolution and emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have resulted in challenges to vaccine and antibody efficacy. The emergence of each new variant...